Specifically, rates of HR-positive and ERBB2-negative breast cancer are generally increasing, while in more recent years rates of HR-positive and ERBB2-positive and HR-negative and ERBB2-positive cancers are decreasing. This evidence concerns the gene ERBB2 and breast cancer.